FDA Approves Ontruzant

By :

New Ebola Vaccine for Exposure Risk

January 21, 2019 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Ontruzant (trastuzumab-dttb), a biosimilar referencing Herceptin (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease. #fda #FDA #Approval #Drug
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF DIC Team

Approval of new treatment for adults with partial-onset seizures

PHAF Team

Navigating the New Clozapine REMS

PHAF Team

LENVIMA (lenvatinib) capsules

PHAF Team

FDA approval : first treatment for frequent urination at night

PHAF Team

A new eczema drug Dupixent : FDA Approval

PHAF Team

New drug that can prevent breast cancer growth identified

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.